1. Patients must have an estimated survival of at least 4 weeks
2. Karnofsky Performance Status Scale (KPS) of 60-100.
3. Patients' laboratory values had to meet these restrictions: hemoglobin\>8 g/dL, platelets\>70\*109/L, white blood cells\>4\*109/L.
4. Patients must sign a study specific informed consent form prior to study entry
You may not be if
1. Patients had major medical illnesses or psychiatric impairments which will prevent completion of the protocol therapy
2. had received previous brain irradiation
3. could not be regularly followed
4. with leptomeningeal involvement
Clareo Health | Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
